
Global Newsroom
Recent News Releases
Coronavirus Information
During the COVID-19 outbreak, CSL is here for our patients and our larger world community.
Ukraine Information
CSL condemns the invasion of Ukraine and we are supporting multiple humanitarian relief efforts to help those impacted by this unjust act.
Latest CSL News
Latest CSL News
CSL Welcomes US Court Ruling
Statement attributable to Greg Boss, Executive Vice President - Legal, and CSL Limited Group General Counsel.
CSL recognised in AFR Best Places to Work.
CSL ranked fourth on the Health Industry list, from a total of more than 750 organisations nominated in all sectors across Australia and New Zealand.
FDA Clearance of Plasma Collection Technology
CSL Plasma U.S. collection centers are preparing to undergo implementation of newly cleared Rika Plasma Donation System, with limited market release beginning in Colorado centers.
Forbes Ranks CSL Among America's Best Employers
With 25,000 global employees, CSL is one of 500 Large Employers recognized across 25 industry sectors
CSL Publishes Vifor Offer Prospectus
CSL Behring AG Publishes Offer Prospectus On Public Tender Offer For All Publicly Held Shares Of Vifor Pharma Ltd.
CSL Joins StartX Community
Through the StartX partnership, CSL will access an ecosystem of early stage biotech, medtech and digital healthcare ventures, exploring opportunities to collaborate around disruptive technologies and build relationships with entrepreneurial founders.
CSL Committed to AZ COVID Vaccine
CSL Reaffirms Commitment to Manufacture AstraZeneca COVID Vaccine into 2022
CSL Requires COVID-19 Vaccination
CSL Requires COVID-19 Vaccination for On-Site Employees and Visitors
Applications Open for Fellowships
$2.5 Million Funding Available to Australian Biomedical Researchers
CSL welcomes the Patent Box Policy
New Patent Box policy will benefit domestic commercialisation of medical research
CSL welcomes domestic mRNA vaccine development
Onshore mRNA manufacturing will build Australian capability for next generation vaccine technologies
CSL Behring Announces Agreement with uniQure
Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.
uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.
2020 RAI Awardees Announced
Four Australian Research Programs to be Fast-Tracked in Partnership with CSL
Media Contacts
Christina Hickie
CSL Limited
Senior Manager, Communications
Phone: +61 429 609 762